LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Human CRP-Levels Compared Using Point-of-Care Methods

By LabMedica International staff writers
Posted on 08 Oct 2019
Print article
Image: The ABX Micros CRP 200 hematology analyzer (Photo courtesy of Horiba Medical).
Image: The ABX Micros CRP 200 hematology analyzer (Photo courtesy of Horiba Medical).
Due to the rapid increase of the C-reactive protein (CRP) concentration in the event of an inflammatory disease, CRP is regarded as one of the most important acute phase proteins. Inflammation and CRP play an important role in operations, trauma, mental stress, myocardial infarction and neoplastic diseases.

The use of point-of-care (POC) methods and the measurements of CRP as a diagnostic marker have both increased over the past years. This has led to an increase in POC-methods analyzing CRP. High CRP levels are often seen as an indication for the proscribing of antibiotics. The quality of POC-systems compared to routine diagnostic measurements for the analysis of CRP is thereby of major importance, since many small practices will use POC-methods.

Biomedical scientists from the Salzburg University of Applied Sciences (Puch bei Hallein, Austria) compared POC and classical clinical chemistry methods, using 199 anonymized patient samples (104 male and 95 female patients aged from 31 to 96 years). The blood samples were selected based on a CRP concentration of more than 100 mg/L as measured by the Architect ci8200SR.

Comparisons were then made with ABX Micros CRP 200 (Horiba, Kyoto, Japan) and the i-CHROMA system. The CRP-levels on the Architect ci8200 were detected using serum samples and the method is based on a turbidimetric assay. EDTA-whole blood was used for the test procedure with the i-CHROMA and ABX. The ABX also works with a turbidimetric assay system and the i-CHROMA is based on a fluorescence sandwich immunoassay. The values from the i-CHROMA were used corrected for the hematocrit values.

The scientists reported that the results of the Architect ci8200 and the ABX showed significant differences when compared to the results of the i-CHROMA with hematocrit corrections. In addition, the values of the Architect ci8200 and the ABXs were also significantly different. Nevertheless, the most pronounced differences were seen when comparing the i-CHROMA with the Architect ci8200 with detected differences of up to 147.6 mg/L. Comparing the values of the i-CHROMA with the ABX resulted in differences of up to 92.7 mg/L. The lowest maximal difference of 39.4 mg/L is seen when comparing the results of the Architect ci8200 and the ABX.

The authors concluded that the measured CRP concentrations of the i-CHROMA strongly differ in the higher CRP concentration range when compared to the measurements performed on routine diagnostic equipment. The significantly reduced CRP measurements can strongly affect patient safety and result in wrong diagnostic measures. The study was published on September 19, 2019, in the journal Practical Laboratory Medicine.

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.